Search Result

Results for "

Kinase inhibition

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AIM2 (2) AMPK (3) Antibiotic (1) Apoptosis (13) ATM/ATR (3) Aurora Kinase (1) Autophagy (7) Bacterial (5) Bcr-Abl (2) Biochemical Assay Reagents (2) Btk (8) c-Kit (2) c-Met/HGFR (4) Calcium Channel (1) CaMK (3) Casein Kinase (6) Caspase (1) CDK (7) Chloride Channel (2) COX (2) Cytochrome P450 (1) Dihydroorotate Dehydrogenase (1) DNA-PK (1) DNA/RNA Synthesis (5) DYRK (1) EGFR (9) Endogenous Metabolite (6) ERK (6) FAK (2) Ferroptosis (1) FGFR (3) FLT3 (2) G Protein-coupled Receptor Kinase (GRK) (2) GABA Receptor (1) GSK-3 (2) HIV (2) HSV (1) IKK (5) IRAK (3) Isotope-Labeled Compounds (3) Itk (2) JAK (7) Kinesin (1) Lipase (1) MAP3K (2) MAPKAPK2 (MK2) (1) MARK (1) MDM-2/p53 (1) MEK (3) Microtubule/Tubulin (2) mTOR (3) Myosin (1) Necroptosis (1) NF-κB (6) p38 MAPK (7) PDGFR (5) Phosphatase (2) Phosphodiesterase (PDE) (3) PI3K (11) PI4K (1) Pim (1) PKA (6) PKC (8) PKD (1) PKG (2) Polo-like Kinase (PLK) (4) Prostaglandin Receptor (1) PROTACs (1) Pyruvate Kinase (2) Raf (3) Ras (1) Reactive Oxygen Species (1) RET (4) Ribosomal S6 Kinase (RSK) (1) RIP kinase (2) ROS Kinase (1) Salt-inducible Kinase (SIK) (1) Sodium Channel (3) SphK (2) Src (3) STAT (2) Syk (2) TAM Receptor (2) Tie (1) TNF Receptor (2) Trk Receptor (2) Tyrosinase (1) ULK (1) VEGFR (8) VSV (1) Wnt (1)
By Research Areas:	Cancer (91) Cardiovascular Disease (13) Infection (7) Inflammation/Immunology (44) Metabolic Disease (7) Neurological Disease (14)
Click Chemistry:	Alkynes (3)

158

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162255

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

HY-148314

ROS kinases-IN-2	ROS Kinase	Cancer
ROS kinases-IN-2 is a ROS kinase inhibitor with 21.53% inhibition at 10 μM .

HY-15979

H-89 Maximum Cited Publications 124 Publications Verification	PKA Autophagy	Neurological Disease
H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (*protein kinase* A) with IC₅₀** of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.

HY-15979A

H-89 dihydrochloride Maximum Cited Publications 124 Publications Verification	PKA Autophagy	Others
H-89 dihydrochloride is a potent and selective inhibitor of protein kinase A (PKA) with an IC₅₀ of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase.

HY-P1479A

Calmodulin-Dependent Protein Kinase II(290-309) acetate	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-144706

Axl-IN-3	TAM Receptor	Cancer
Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC₅₀ of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases .

HY-P1479

Calmodulin-Dependent Protein Kinase II (290-309)	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-P3841

Protein Kinase C (beta) Peptide	PKC	Others
Protein Kinase C β Peptide is a peptide fragment of Protein Kinase Cβ. Protein Kinase Cβ is related with hyperglycemia decreases endothelium-derived nitric oxide. Inhibition of Protein kinase Cβ prevents the reduction in endothelium-dependent vasodilation induced by acute hyperglycemia .

HY-N3702

Dehydroabietinol	Syk	Inflammation/Immunology
Dehydroabietinol is an abietane diterpenoid. Dehydroabietinol has kinase inhibition activity for spleen tyrosine kinase (SYK) with an IC₅₀ value of 46.4 μM. Dehydroabietinol can be used for the research of immune-mediated disease .

HY-171252

EGFR-IN-145	EGFR	Cancer
EGFR-IN-145 (compound 7c) is an EGFR kinase inhibitor. At a concentration of 20 μM, EGFR-IN-145 has an inhibition rate of 52.7% on EGFR-wild type kinase .

HY-141864

ITK/TRKA-IN-1	Itk	Inflammation/Immunology
ITK/TRKA-IN-1 is a dual inhibitor of *IL-2-inducible T-cell kinase* (ITK) and tropomyosin receptor kinase A (TRKA) with an IC₅₀** value of 1.0 nM and 96 % inhibition, respectively.

HY-116529

Lamellarin E	Others	Others
Lamellarin E is a biologically active marine alkaloid, while the Lamellarin series of alkaloids show potential cytotoxicity, topoisomerase I inhibition, protein kinase inhibition, multidrug resistance reversal, and anti-HIV-1 activity .

HY-148112

Casein kinase 1δ-IN-1	Casein Kinase	Neurological Disease
Casein kinase 1δ-IN-1 (compound 822) is an inhibitor of *casein kinase* 1 delta (CK1δ*), exhibits inhibition* of greater than 5%. Casein kinase 1δ-IN-1 can be used for neurodegenerative disorders such as Alzheimer's disease research .

HY-B1898

Metadoxine	PKA	Metabolic Disease
Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein (PKA-CREB) pathway.

HY-49073

p38 MAP Kinase Inhibitor Ⅵ	p38 MAPK	Cancer
p38 MAP Kinase Inhibitor VI (compound c32) is a p38 MAPK inhibitor with an inhibition rate of 24% .

HY-15802

WZ4003 5 Publications Verification	AMPK	Cancer
WZ4003 is the first potent and highly specific NUAK kinase inhibitor with IC₅₀ of 20 nM/100 nM for NUAK1 (ARK5)/NUAK2, without significant inhibition on other 139 kinases.

HY-112266

MARK-IN-4	MARK AMPK	Neurological Disease
MARK-IN-4 is a potent microtubule affinity regulating kinase (MARK) inhibitor with an IC₅₀ of 1 nM. Inhibition of microtubule affinity regulating kinase (MARK) represents a potentially attractive means of arresting neurofibrillary tangle pathology in Alzheimer's disease .

HY-150027

Multi-kinase-IN-3	VEGFR PDGFR	Cancer
Multi-kinase-IN-3 (compound 2) is a potent angiokinase inhibitor. Multi-kinase-IN-3 shows inhibition activity against VEGFR-2 and PDGFRβ, with IC₅₀ values of 58.3 and 55 nM, respectively .

HY-164041

Staurosporine-Boc	PKC	Others
Staurosporine-Boc, a natural product isolated from the actinomyces Streptomyces staurosporeus, is a potent non-selective inhibitor of protein kinase. Staurosporine-Boc inhibits a variety of protein kinases, including protein kinase C (PKC), tyrosine kinase, and serine/threonine kinase. Because of its broad inhibition profile, Staurosporine-Boc is widely used as a tool compound in biological research, especially when studying cell signaling pathways .

HY-112082

BAY885	ERK	Cancer
BAY885 is a highly potent and selective ERK5 inhibitor with an IC₅₀ of 35 nM. BAY885 shows weak inhibition on others kinases .

HY-149075

MR22	Salt-inducible Kinase (SIK)	Cancer
MR22 is a potent pan-SIK (salt-inducible kinase) inhibitor. MR22 no longer exhibits activity on STE group kinases and displays excellent selectivity in a representative kinase panel. MR22-dependent SIK inhibition led to centrosome dissociation and subsequent cell-cycle arrest in ovarian cancer cells .

HY-144381

Glutamate-5-kinase-IN-1	Bacterial	Infection
Glutamate-5-kinase-IN-1 (compound 50) is a potent glutamate-5-kinase (G5K) inhibitor with an MIC (minimum inhibitory concentration) of 4.1 µM. Glutamate-5-kinase-IN-1 shows G5K inhibition by alters the ATP binding site architecture for enzyme recognition. Glutamate-5-kinase-IN-1 has the potential for the research of anti-TB agents .

HY-144382

Glutamate-5-kinase-IN-2	Bacterial	Infection
Glutamate-5-kinase-IN-2 (compound 54) is a potent glutamate-5-kinase (G5K) inhibitor with an MIC (minimum inhibitory concentration) of 4.2 µM. Glutamate-5-kinase-IN-2 shows G5K inhibition by promotes conformational changes at the L-glutamate binding site. Glutamate-5-kinase-IN-2 has the potential for the research of anti-TB agents .

HY-149415

Multi-kinase-IN-5	RET FGFR VEGFR c-Kit c-Met/HGFR PDGFR Raf	Cancer
Multi-kinase-IN-5 (compound 15c) is a promising multi-kinase inhibitory agent. Multi-kinase-IN-5 inhibits a panel of protein kinases (RET, KIT, cMet, VEGFR1,2, FGFR1, PDGFR and BRAF), showing % inhibition of 74%, 31%, 62%, 40%, 73%, 74%, 59%, and 69%, respectively, and IC₅₀ of 1.287, 0.117 and 1.185 μM against FGFR1, VEGFR, and RET kinases, respectively .

HY-141896

RET-IN-7	RET	Cancer
RET-IN-7 demonstrates potent in vitro RET kinase inhibition and robust in vivo efficacy in RET-driven tumor xenografts upon multiday dosing in mice.

HY-15814

HG-7-85-01	Bcr-Abl PDGFR c-Kit Src JAK Apoptosis	Cancer
HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR and RET with IC₅₀s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC₅₀>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression .

HY-160708

Tie2 kinase inhibitor 3	Tie	Cancer
Tie2 kinase inhibitor 3 (compound 63) is a potent Tie-2 kinase inhibitor with good oral activity (IC₅₀=30 nM). Tie2 kinase inhibitor 3 inhibits phosphorylation and signaling of Tie-2 by competing with the ATP binding site of Tie-2 kinase. This inhibition affects the stability and maturity of blood vessels, which has an impact on tumor angiogenesis. Tie2 kinase inhibitor 3 can be used to restrict tumor growth and regulate angiogenesis .

HY-P10346

smMLCK peptide Smooth-Muscle Myosin Light-Chain Kinase (796-815)	Myosin	Cardiovascular Disease Inflammation/Immunology
smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction .

HY-125068

RPR203494	Cytochrome P450 p38 MAPK	Inflammation/Immunology
RPR203494 is a potent inhibitor against CYP isozymes. RPR203494 shows inhibition against p38 kinase with an IC₅₀ value of 9 nM and an EC₅₀ value of 60 nM. RPR203494 demonstrates an inhibition of hepatic Cytochrome P450. RPR203494 is promising for research of rheumatoid arthritis (RA) .

HY-132808

Atuzabrutinib SAR 444727; PRN473	Btk	Inflammation/Immunology
Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling .

HY-164413

CLM3	VEGFR EGFR RET Apoptosis	Cancer
CLM3, a pyrazolopyrimidine derivative, is a multiple tyrosine kinase inhibitor. CLM3 shows antiproliferative and proapoptotic activity on endothelial and cancer cells, synergistically enhanced by SN38 (HY-13704). These effects are mainly due to its inhibition of phosphorylation of VEGFR-2, EGFR and RET tyrosine kinases and their related signaling pathways .

HY-12461

WS6	PI3K EGFR GABA Receptor FLT3 IKK	Neurological Disease Metabolic Disease Inflammation/Immunology
WS6 is an IkB kinase and EBP1 inhibitor, with IC₅₀ values of 0.24 nM, 0.21 nM, and 40.48 nM in MV4-11, MOLM13, and K562 cells, respectively. WS6 promotes the proliferation of alpha and beta cells in the pancreas, has antioxidant and anti-inflammatory activities, and can alleviate depression like behavior in rats ^[1][2][4].

HY-12299

WH-4-023 4 Publications Verification Dual LCK/SRC inhibitor	Src	Cancer
WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC₅₀ of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.

HY-10966

SB-590885 5+ Cited Publications	Raf	Cancer
SB-590885 is a potent?B-Raf?inhibitor with?K_i?of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.

HY-125762

Tyrosinase-IN-16	Tyrosinase	Cancer
Tyrosinase-IN-16 (compound 19a) is a tyrosine kinase (Tyrosinase) inhibitor with Ki=470 nM. Tyrosinase-IN-16 is cytotoxic to B16F10 cells, with >90% inhibition at 20 μM .

HY-144687

ATM Inhibitor-4	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-4 (compound 39) is a potent and selective ATM inhibitor, with an IC₅₀ of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability .

HY-12900

RB-005	SphK	Inflammation/Immunology Cancer
RB-005 is a selective inhibitor of sphingosine kinase 1 (SK1) (IC₅₀=3.6 µM), with weaker inhibition of another isoenzyme, SK2. The selective inhibition of RB-005 helps to distinguish the biological functions and roles of SK1 and SK2, which can be used in the study of inflammatory diseases and cancer .

HY-N2484

Methylnissolin Astrapterocarpan	PDGFR ERK	Cardiovascular Disease
Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC₅₀ of 10 μM. Methylnissolin inhibits PDGF-BB-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERIC1/2) mitogen-activated protein (MAP) kinase. Methylnissolin inhibits PDGF-BB-induced vascular smooth muscle cell proliferation by inhibition of the ERK1/2 MAP kinase cascade .

HY-147695

c-Met-IN-12	c-Met/HGFR	Cancer
c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC₅₀ of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .

HY-15798

UNC2881	VSV TAM Receptor	Cardiovascular Disease
UNC2881 is an orally active and specific Mer kinase inhibitor, inhibits steady-state Mer kinase phosphorylation with an IC₅₀ value of 22 nM. UNC2881 shows additional inhibition against Axl and Tyro with IC₅₀s of 360 nM and 250 nM, respectively. UNC2881 potently inhibits collagen-induced platelet aggregation, can be used for pathologic thrombosis research .

HY-W110242A

(S)-CPP sodium	Endogenous Metabolite	Cardiovascular Disease
(S)-CPP sodium serves as an inhibitor of the branched-chain α-ketoacid dehydrogenase complex (BCKDC) kinase, commonly referred to as BDK or keto acid dehydrogenase kinase. As a negative regulator of BCKDC activity, the inhibition of BDK by (S)-CPP (with an IC50 of 6.3 μM) results in the activation of the complex and a notable decrease in plasma levels of leucine/isoleucine and valine in wild-type mice.

HY-121998

Binucleine 2	Aurora Kinase	Others
Binucleine 2 is an isoform-specific and ATP-competitive inhibitor of Drosophila Aurora B kinase (Ki=0.36 μM), a kinase involved in cell division. It is specific for Drosophila Aurora B kinase, inhibiting it in a dose-dependent manner, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 μM. Binucleine 2 induces mitotic and cytokinesis defects in Drosophila Kc167 cells. It prevents Drosophila S2 cells from assembling a contractile ring during cell division when used at a concentration of 40 μM but does not affect ring ingression, suggesting that Aurora B kinase activity is not required for that step.

HY-P1597

Malantide 1 Publications Verification	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by *cAMP-dependent protein kinase* (PKA)** on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for PKC with a K_m of 16 μM .

HY-112400

Bisindolylmaleimide V BIM V	Ribosomal S6 Kinase (RSK)	Cancer
Bisindolylmaleimide V is a cell-permeable negative control for protein kinase C inhibition studies with an IC₅₀ value over 100 µM . Bisindolylmaleimide V blocks the activation of mitogen-stimulated protein kinase p70 ^s6k/p85 ^s6k (S6K) in vivo with an IC₅₀ of 8 µM .

HY-108431

MN58b	Apoptosis	Cancer
MN58b is a selective *choline kinase* α (CHKα)** inhibitor, and results in inhibition of phosphocholine synthesis. MN58b reduces cell growth through the induction of apoptosis, and also has antitumoral activity .

HY-150561

Trk-IN-20	Trk Receptor	Cancer
Trk-IN-20 is a kind of 3-vinylindazole derivatives. Trk-IN-20 suppresses Trk kinases functions by phosphorylation inhibition of TrkA/B/C with IC₅₀ values of 1.6 nM, 2.9 nM and 2.0 nM, respectively .

HY-12037A

Rigosertib 5 Publications Verification ON-01910	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle . Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 with an IC₅₀ of 9 nM .

HY-P1597A

Malantide TFA	PKA PKC	Cancer
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by *cAMP-dependent protein kinase* (PKA)** on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide TFA is also an efficient substrate for PKC with a K_m of 16 μM .

HY-164840

Clofarabine-5'-triphosphate Clofarabine-TP	DNA/RNA Synthesis	Cancer
Clofarabine-5'-triphosphate is the metabolite of Clofarabine (HY-A0005) by deoxycytidine kinase (dCK) phosphorylation. Clofarabine-5'-triphosphate exhibits cytotoxicity in cancer cells through inhibition of DNA synthesis and DNA repair .

HY-169231

BCR-ABL-IN-10	Bcr-Abl	Cancer
BCR-ABL-IN-10 (compound B4) is a covalent and aryl vinyl sulfate (AVS)-containing BCR-ABL inhibitor with an IC₅₀ of 43.1 nM for ABL kinase. BCR-ABL-IN-10 forms a covalent and stable adduct with ABL kinase, leading to sustained inhibition of endogenous BCR-ABL activities. BCR-ABL-IN-10 can be used for the study of chronic myeloid leukemia (CML) .

Cat. No.	Product Name

HY-L044

Nucleotide Compound Library

551 compounds

Nucleoside and nucleotide analogues are synthetic, chemically modified compounds that have been developed to mimic their physiological counterparts in order to exploit cellular metabolism and subsequently be incorporated into DNA and RNA to inhibit cellular division and viral replication. In addition to their incorporation into nucleic acids, nucleoside and nucleotide analogues can interact with and inhibit essential enzymes such as human and viral polymerases (that is, DNA-dependent DNA polymerases, RNA-dependent DNA polymerases or RNA-dependent RNA polymerases), kinases, ribonucleotide reductase, DNA methyltransferases, purine and pyrimidine nucleoside phosphorylase and thymidylate synthase. These actions of nucleoside and nucleotide analogues have potential therapeutic benefits — for example, in the inhibition of cancer cell growth, the inhibition of viral replication as well as other indications.

MCE offers a unique collection of 551 nucleotide compounds including nucleotide, nucleoside and their structural analogues. MCE Nucleotide Compound Library is a useful tool to discover anti-cancer and antiviral drugs for high throughput screening (HTS) and high content screening (HCS).

HY-L015

PI3K/Akt/mTOR Compound Library

680 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 680 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Type

HY-W698686

β-Galactosyl-C18-ceramide

Cell Assay Reagents

β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition.

Cat. No.	Product Name	Target	Research Area

HY-P1479A

Calmodulin-Dependent Protein Kinase II(290-309) acetate	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-P1597

Malantide 1 Publications Verification	PKA PKC	Cancer
Malantide is a synthetic dodecapeptide derived from the site phosphorylated by *cAMP-dependent protein kinase* (PKA)** on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide is also an efficient substrate for PKC with a K_m of 16 μM .

HY-P1479

Calmodulin-Dependent Protein Kinase II (290-309)	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-P3841

Protein Kinase C (beta) Peptide	PKC	Others
Protein Kinase C β Peptide is a peptide fragment of Protein Kinase Cβ. Protein Kinase Cβ is related with hyperglycemia decreases endothelium-derived nitric oxide. Inhibition of Protein kinase Cβ prevents the reduction in endothelium-dependent vasodilation induced by acute hyperglycemia .

HY-P10346

smMLCK peptide Smooth-Muscle Myosin Light-Chain Kinase (796-815)	Myosin	Cardiovascular Disease Inflammation/Immunology
smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction .

HY-P1597A

Malantide TFA	PKA PKC	Cancer
Malantide TFA is a synthetic dodecapeptide derived from the site phosphorylated by *cAMP-dependent protein kinase* (PKA)** on the β-subunit of phosphorylase kinase. Malantide TFA is a highly specific substrate for PKA with a K_m of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts . Malantide TFA is also an efficient substrate for PKC with a K_m of 16 μM .

HY-P1834

MARCKS Peptide(151-175), Phosphorylated	Peptides	Inflammation/Immunology
MARCKS Peptide(151-175), Phosphorylated is a phosphorylated peptide corresponding to the basic effector domain of myristoylated alanine-rich protein kinase C substrate protein (MARCKS). Phosphorylation of MARCKS Peptide (151-175) reverses its inhibition of phospholipase C (PLC)-catalyzed hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) .

HY-P10316

CaMKI(299-320) Calmodulin-Dependent Protein Kinase I (299-320) Binding Domain	CaMK	Others
CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca ²⁺-CAM (K_d≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .

HY-P5452

PKCd (8-17)	PKC	Others
PKCd (8-17) is a biological active peptide. (This peptide is derived from the V1 domain of protein kinase C (PKC)d. It inhibits phorbol 12-myristate 13-acetate (PMA)-induced PKCd translocation and activation. Inhibition of PKCd reduces ischemia damage in cardiac and cerebral cells, induces proliferation of fibroblasts, and inhibits graft coronary artery disease in mice.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2484

Methylnissolin Astrapterocarpan	Cardiovascular Disease Monophenols Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants Other Flavonoids Disease Research Fields	PDGFR ERK
Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC₅₀ of 10 μM. Methylnissolin inhibits PDGF-BB-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERIC1/2) mitogen-activated protein (MAP) kinase. Methylnissolin inhibits PDGF-BB-induced vascular smooth muscle cell proliferation by inhibition of the ERK1/2 MAP kinase cascade .

HY-N6246

Asperulosidic Acid	Iridoids Classification of Application Fields Terpenoids Source classification Rubiaceae Plants Morinda officinalis How Inflammation/Immunology Disease Research Fields	NF-κB ERK
Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities . ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways .

HY-13295

Vinpocetine 5+ Cited Publications Ethyl apovincaminate	Cardiovascular Disease Structural Classification Neurological Disease Classification of Application Fields Anti-aging Source classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Apocynaceae Alkaloids Piperidine Alkaloids Disease Research Fields Cancer	Sodium Channel IKK Phosphodiesterase (PDE)
Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na ⁺ channels. The IC₅₀ value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting *IκB kinase* complex (IKK)**, and has been widely used for the treatment of cerebrovascular disorders .

HY-N0822

Shikonin Maximum Cited Publications 42 Publications Verification C.I. 75535; Isoarnebin 4	Quinones Structural Classification Classification of Application Fields Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Boraginaceae Disease Research Fields Cancer	Chloride Channel Pyruvate Kinase NF-κB TNF Receptor HIV AIM2
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC₅₀ of 6.5 μM . Shikonin is a specific *pyruvate kinase* M2 (PKM2)** inhibitor and can also inhibit TNF-α and NF-κB pathway . Shikonin decreases exosome secretion through the inhibition of glycolysis . Shikonin inhibits AIM2 inflammasome activation .

HY-N0385

Gomisin J 3 Publications Verification	Cardiovascular Disease Monophenols Classification of Application Fields Source classification Lignans Phenols Phenylpropanoids Plants Schisandraceae Disease Research Fields Schisandra chinensis (Turcz.) Baill.	AMPK Calcium Channel
Gomisin J is a small molecular weight lignan found in Schisandra chinensis and has been demonstrated to have vasodilatory activity . Gomisin J suppresses lipid accumulation by regulating the expression of lipogenic and lipolytic enzymes and inflammatory molecules through activation of AMPK, LKB1 and *Ca ²⁺/calmodulin-dependent protein kinase* II** and inhibition of fetuin-A in HepG2 cells. gomisin J has potential benefits in treating nonalcoholic fatty liver disease .

HY-N0632

Esculentoside A 2 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Phytolacca acinosa Roxb. Plants Inflammation/Immunology Disease Research Fields Phytolaccaceae	COX NF-κB
Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta . Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models , has selective inhibitory activity towards cyclooxygenase-2 (COX-2) . Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways .

HY-N3702

Dehydroabietinol	Structural Classification Terpenoids Verbenaceae Callicarpa bodinieri Levl. Source classification Diterpenoids Plants	Syk
Dehydroabietinol is an abietane diterpenoid. Dehydroabietinol has kinase inhibition activity for spleen tyrosine kinase (SYK) with an IC₅₀ value of 46.4 μM. Dehydroabietinol can be used for the research of immune-mediated disease .

HY-116529

Lamellarin E	Structural Classification Alkaloids Microorganisms Other Alkaloids Source classification	Others
Lamellarin E is a biologically active marine alkaloid, while the Lamellarin series of alkaloids show potential cytotoxicity, topoisomerase I inhibition, protein kinase inhibition, multidrug resistance reversal, and anti-HIV-1 activity .

HY-N6246R

Asperulosidic Acid (Standard)	Structural Classification Iridoids Terpenoids Source classification Rubiaceae Plants Morinda officinalis How	NF-κB ERK
Asperulosidic Acid (Standard) is the analytical standard of Asperulosidic Acid. This product is intended for research and analytical applications. Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities . ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways .

HY-13295R

Vinpocetine (Standard)	Apocynaceae Alkaloids Piperidine Alkaloids Structural Classification Source classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don	Sodium Channel IKK Phosphodiesterase (PDE)
Vinpocetine (Standard) is the analytical standard of Vinpocetine. This product is intended for research and analytical applications. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na ⁺ channels. The IC₅₀ value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting *IκB kinase* complex (IKK)**, and has been widely used for the treatment of cerebrovascular disorders .

HY-N0822R

Shikonin (Standard)	Quinones Structural Classification Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Boraginaceae	Chloride Channel Pyruvate Kinase NF-κB TNF Receptor HIV AIM2
Shikonin (Standard) is the analytical standard of Shikonin. This product is intended for research and analytical applications. Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC₅₀ of 6.5 μM . Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway . Shikonin decreases exosome secretion through the inhibition of glycolysis . Shikonin inhibits AIM2 inflammasome activation .

HY-N0632R

Esculentoside A (Standard)	Triterpenes Structural Classification Terpenoids Source classification Phytolacca acinosa Roxb. Plants Phytolaccaceae	COX NF-κB
Esculentoside A (Standard) is the analytical standard of Esculentoside A. This product is intended for research and analytical applications. Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta . Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models , has selective inhibitory activity towards cyclooxygenase-2 (COX-2) . Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways .

HY-112356

Scytonemin	Structural Classification Alkaloids Microorganisms Classification of Application Fields Sunscreen Source classification Cosmetic Research Indole Alkaloids	Apoptosis Reactive Oxygen Species Polo-like Kinase (PLK)
Scytonemin is a hydrophobic alkaloid pigment that can be isolated from the outer sheath of cyanobacteria. Scytonemin has protective function against short-wave solar ultraviolet (UV) radiation, which can reduce the generation of reactive oxygen species (ROS) and the formation of DNA damage. Scytonemin also has anti-inflammatory and anti-proliferative activities, produces concentration-dependent inhibition (IC₅₀=2.0 μM) of polo-like kinase 1 (PLK1)-mediated cdc25C phosphorylation, and plays an important role in regulating the G2/M transition in the cell cycle. It can be used in the research of cancer, acute inflammation and sunscreen cosmetics .

HY-155156

PF-07238025	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-155157

PF-07247685	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-N6871

Abietic acid	Infection Structural Classification Colophony Classification of Application Fields Pinaceae Ketones, Aldehydes, Acids Metabolic Disease Plants Inflammation/Immunology Disease Research Fields	Bacterial IKK Ferroptosis
Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .

Cat. No.	Compare	Product Name	Species	Source

HY-P70299

	NME1/NDPKA Protein, Human (His) rHuNucleoside diphosphate Kinase A/NDPKA, His; Nucleoside Diphosphate Kinase A; NDK A; NDP Kinase A; Granzyme A-Activated DNase; GAAD; Metastasis inhibition Factor nm23; Tumor Metastatic Process-Associated Protein; nm23-H1; NME1; NDPKA; NM23	Human	E. coli
	The NME1/NDPKA protein plays a crucial role in the synthesis of nucleoside triphosphates and exhibits multiple activities, including nucleoside diphosphate kinase, serine/threonine-specific protein kinase, geranyl and farnesyl pyrophosphate kinase, histidine protein kinase and 3'-5' exonuclease functions. NME1/NDPKA Protein, Human (His) is the recombinant human-derived NME1/NDPKA protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-16305S1

Maribavir-d6 TFA
Maribavir-d6 TFA (1263W94-d6 TFA; BW1263W94-d6 TFA; GW257406X-d6 TFA) is a deuterium labeled Maribavir (HY-16305). Maribavir is an orally active antiviral agent for cytomegalovirus (CMV) through inhibition of protein kinase UL97 and the following CMV DNA replication .

HY-17422S1

Acyclovir-d4

Acyclovir-d₄ is the deuterium labeled Acyclovir. Acyclovir (Aciclovir) is a guanosine analogue and an orally active antiviral agent. Acyclovir inhibits HSV-1 (IC50 of 0.85 μM), HSV-2 (IC50 of 0.86 μM) and varicella-zoster virus. Acyclovir can be phosphorylated by viral thymidine kinase (TK), and Acyclovir triphosphate interferes with viral DNA polymerization through competitive inhibition with guanosine triphosphate and obligatory chain termination[1][2][3]. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia[4].

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-13295S

Vinpocetine-d5

Vinpocetine-d₅ is the deuterium labeled Vinpocetine. Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders[1][2][3].

HY-W698686S

β-Galactosyl-C18-ceramide-d35

β-Galactosyl-C18-ceramide-d₃5 is deuterium labeled β-Galactosyl-C18-ceramide. β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81289

	NM23A Antibody (YA1002) NME1; NDPKA; NM23; Nucleoside diphosphate Kinase A; NDK A; NDP Kinase A; Granzyme A-activated DNase; GAAD; Metastasis inhibition factor nm23; Tumor metastatic process-associated protein; nm23-H1	WB	Human, Mouse, Rat
	NM23A Antibody (YA1002) is a non-conjugated IgG1 antibody, targeting NM23A, with a predicted molecular weight of 17 kDa (observed band size: 16,18 kDa). NM23A Antibody (YA1002) can be used for WB experiment in human, mouse, rat background.

HY-P81289A

	NM23A Antibody (YA1003) NME1; NDPKA; NM23; Nucleoside diphosphate Kinase A; NDK A; NDP Kinase A; Granzyme A-activated DNase; GAAD; Metastasis inhibition factor nm23; Tumor metastatic process-associated protein; nm23-H1	WB	Human
	NM23A Antibody (YA1003) is a non-conjugated IgG antibody, targeting NM23A, with a predicted molecular weight of 17 kDa (observed band size: 17 kDa). NM23A Antibody (YA1003) can be used for WB experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-130530

AP-C5		Alkynes
AP-C5 displays selective inhibition of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC₅₀ of 7.2, which can be used for the research of diarrheal disease . AP-C5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-125387

TOP1210		Alkynes
TOP1210 is a narrow-spectrum tyrosine kinase inhibitor with potent inhibitory activity against P38α, Src, and Syk kinases. TOP1210 effectively reduced proinflammatory cytokines released by peripheral blood monocytes, primary macrophages, HT29 cells, inflammatory cells in ulcerative colitis (UC) biopsies, and myofibroblasts isolated from inflamed colonic UC mucosa. TOP1210 showed significant anti-inflammatory effects in cell experiments and UC biopsies, superior to some selective kinase inhibitors. The multi-kinase inhibition of TOP1210 provides the possibility of obtaining a wider range of therapeutic effects, especially in the regulation of autoimmune responses .

HY-129510

4-Methyl erlotinib		Alkynes
4-Methyl erlotinib, is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. 4-Methyl erlotinib potently inhibits EGF-mediated tumor cell mitosis by reducing EGFr-specific tyrosine phosphorylation. Using a mouse model of human tumor transplantation, 4-Methyl erlotinib demonstrated significant and sustained suppression of EGFr phosphotyrosine levels, resulting in significant growth inhibition of EGFr-dependent human cancers .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks